Zobrazeno 1 - 10
of 114
pro vyhledávání: '"S, Ressler"'
Autor:
Shaun Bulsara, Julie A. Boom, Kelly S. Ressler, Maria L. Jibaja-Weiss, Jane R. Montealegre, Lindy U. McGee, Haleh Sangi-Haghpeykar
Publikováno v:
Academic Pediatrics. 21:1118-1125
Objective The goal of this study was to categorize reasons behind missed opportunities for human papillomavirus (HPV) vaccine initiation in an under-resourced population and to identify associated patient and clinic characteristics. Methods Manual ch
Autor:
M, Gnant, M, Filipits, R, Greil, H, Stoeger, M, Rudas, Z, Bago-Horvath, B, Mlineritsch, W, Kwasny, M, Knauer, C, Singer, R, Jakesz, P, Dubsky, F, Fitzal, R, Bartsch, G, Steger, M, Balic, S, Ressler, J W, Cowens, J, Storhoff, S, Ferree, C, Schaper, S, Liu, C, Fesl, T O, Nielsen, Peggy, Tsang
Publikováno v:
Annals of Oncology. 25:339-345
PAM50 is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and generate a Risk of Recurrence (ROR) score. It has been developed to be carried out in qualified routine hospital pathology laboratories.One thousand four hundre
Autor:
C Kronberger, Florian Huemer, M Pircher, Claudia Muß, Hubert Hackl, Gabriel Rinnerthaler, S Brechelmacher, Richard Greil, Clemens Hufnagl, Franz Romeder, Brigitte Mlineritsch, S. Ressler, Simon Peter Gampenrieder
Publikováno v:
Cancer Research. 73:P1-08
Background: Biomarkers predicting response or toxicity of bevacizumab containing therapy in breast cancer are of urgent need. The genetic variability of VEGF, its receptor or other genes involved in angiogenesis could explain the inter-patient variab
Autor:
Claudia Muß, Rupert Bartsch, Richard Greil, Franz Romeder, M Pircher, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Brigitte Mlineritsch, S. Ressler, C Sattlberger
Publikováno v:
Cancer Research. 72:P5-20
Background: In November 2011 the FDA withdrew accelerated approval of the breast cancer indication for bevacizumab, because “the drug has not been shown to be safe and effective for this use” (FDA Commissioner M. A. Hamburg, MD). The objective of
Publikováno v:
memo - Magazine of European Medical Oncology. 5:101-104
The discovery of prognostic and predictive biomarkers, enabling the application of more individualized therapies to different molecular breast cancer (BC) subtypes, has already led to changes in BC treatment during the past decades. In this review, t
Publikováno v:
memo - Magazine of European Medical Oncology. 3:185-189
Breast cancer is increasingly recognized a disease very heterogenous in its biological and clinical behaviour. Triple negative breast cancer lacks the expression of estrogen-, progesterone receptors and Her2/neu protein and is characterized by its un
Autor:
M Webersberger, S. Ressler, K Bijuklic, Richard Greil, Brigitte Mlineritsch, M Grundbichler, Lukas Weiss
Publikováno v:
Cancer Research. 70:P3-11
Breast cancer is a heterogenous disease. The inferior prognosis of the triple-negative phenotype was primarily shown in studies, examining outcome by intrinsic subtype, determined via gene expression profiling. Several population based studies, deter
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Klaus Fortschegger, Martina Wei-Fen Chang, Pidder Jansen-Dürr, Günter Lepperdinger, A. Breitwieser, B. Fitzky, Hermann Unterluggauer, S. Ressler, Regina Voglauer, Barbara Hampel, W. Sommergruber, Johannes Grillari
Publikováno v:
Experimental Gerontology. 41:474-481
A convenient way to study processes of aging in distinct human tissues consists of a molecular analysis of cells from the tissue in question, that were explanted and grown in vitro until they reach senescence. Using human umbilical vein endothelial c
Autor:
Wolfgang Hilbe, Veronika Seebacher, Ewald Wöll, Kira Brämswig, Franz Romeder, Clemens Leitgeb, Thomas Kühr, Alexandra Martel, Andreas L. Petzer, Thomas Brodowicz, Michael Girschikofsky, Brigitte Mlineritsch, Ferdinand Ploner, Gerhard Hochreiner, Thomas Bauernhofer, S. Ressler, Herbert Stöger
Publikováno v:
Anti-cancer drugs. 25(7)
Therapeutic options for patients with advanced pretreated soft tissue sarcomas are limited. However, in this setting, sorafenib has shown promising results. We reviewed the data of 33 patients with soft tissue sarcoma treated with sorafenib within a